Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome

被引:88
|
作者
Krejsgaard, T. [1 ,2 ]
Odum, N. [2 ]
Geisler, C.
Wasik, M. A. [3 ]
Woetmann, A. [2 ]
机构
[1] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen N, Denmark
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
cutaneous T-cell lymphoma; Sezary syndrome; immunodeficiency; regulatory T cells; FOXP3; mycosis fungoides; TUMOR-INFILTRATING LYMPHOCYTES; GROWTH-FACTOR-BETA; NF-KAPPA-B; FOXP3; EXPRESSION; FAS-LIGAND; CONSTITUTIVE ACTIVATION; MALIGNANT PROLIFERATION; CD127; LYMPHOMA-CELLS; RECEPTOR;
D O I
10.1038/leu.2011.237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphoma (CTCL) is the term for diseases characterized by primary accumulation of malignant T cells in the skin. Patients with the two predominant clinical forms of CTCL called mycosis fungoides (MF) and Sezary syndrome (SS) characteristically develop severe immunodeficiency during disease progression and consequently patients with advanced disease frequently die of infections and not from the tumor burden. For decades, it has been suspected that the malignant T cells actively drive the evolving immunodeficiency to avoid antitumor immunity, yet, the underlying mechanisms remain unclear. The identification of a subset of highly immunosuppressive regulatory T cells (Tregs) triggered a variety of studies investigating if MF and SS are malignant proliferations of Tregs but seemingly discordant findings have been reported. Here, we review the literature to clarify the role of Tregs in MF and SS and discuss the potential mechanisms driving the immunodeficiency. Leukemia (2012) 26, 424-432; doi:10.1038/leu.2011.237; published online 9 September 2011
引用
收藏
页码:424 / 432
页数:9
相关论文
共 50 条
  • [31] The utility of bexarotene in mycosis fungoides and Sezary syndrome
    Panchal, Manisha R.
    Scarisbrick, Julia J.
    ONCOTARGETS AND THERAPY, 2015, 8 : 367 - 373
  • [32] Immunological milieu in mycosis fungoides and Sezary syndrome
    Miyagaki, Tomomitsu
    Sugaya, Makoto
    JOURNAL OF DERMATOLOGY, 2014, 41 (01): : 11 - 18
  • [33] MYCOSIS-FUNGOIDES AND SEZARY SYNDROME - MALIGNANT CELLS WITH T-CELL ENZYMATIC PROPERTIES
    HEWAT, B
    SIMPKINS, H
    LABORATORY INVESTIGATION, 1979, 40 (02) : 251 - 251
  • [34] CIRCULATING SEZARY CELLS IN MYCOSIS-FUNGOIDES
    WALTHER, JR
    ARONSON, IK
    VARIAKOJIS, D
    MORAN, EM
    CLINICAL RESEARCH, 1976, 24 (04): : A550 - A550
  • [35] Cutaneous T cell lymphoma-mycosis fungoides and Sezary syndrome: an update
    Parker, S. R. S.
    Vincent, B. J.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2009, 144 (04): : 467 - 485
  • [36] LYMPHOCYTES-T MORPHOMETRIC CORRELATION IN THE MYCOSIS-FUNGOIDES AND SEZARY SYNDROME
    IGLESIAS, R
    BEIRAS, A
    VARELA, J
    CUEVAS, J
    REDONDO, VF
    MORFOLOGIA NORMAL Y PATOLOGICA SECCION B-ANATOMIA PATOLOGICA, 1980, 4 (02): : 251 - 256
  • [37] Evaluation of Alitretinoin for the Treatment of Mycosis Fungoides and Sezary Syndrome
    Alhusayen, Raed
    Trang Tuyet Vu
    Almuhanna, Nouf
    Wohlmuth-Wieser, Iris
    Hardin, Jori
    Hughes, John-Douglas Matthew
    Chia, Justin
    Street, Leslie
    Shear, Neil Hartley
    Walsh, Scott Richard
    Gniadecki, Robert
    DERMATOLOGY, 2021, 237 (03) : 479 - 485
  • [38] Prognostic factor analysis in mycosis fungoides/Sezary syndrome
    Diamandidou, E
    Colome, M
    Fayad, L
    Duvic, M
    Kurzrock, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (06) : 914 - 924
  • [39] New trends in the management of mycosis fungoides and Sezary syndrome
    Batycka-Baran, Aleksandra
    Reich, Adam
    Jankowska-Konsur, Alina
    Maj, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2009, 26 (01): : 41 - 55
  • [40] Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sezary Syndrome
    Zic, John A.
    DERMATOLOGIC CLINICS, 2015, 33 (04) : 765 - +